All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
MRD-AML, is RIC enough?
Bookmark this article
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital, Birmingham, UK. We asked, Measurable residual disease (MRD)- AML, is a reduced intensity conditioning regimen enough?
MRD-AML, is RIC enough?
Craddock begins by highlighting why allogeneic hematopoietic stem cell transplantation now plays a role in high risk adult AML. He goes on to outline what we know about the impact of pre-transplant MRD on transplant outcome. Finally, he discusses a lack of randomized data and highlights that myeloablative regimes are safe for fit patients under 50, so there is no reason not to utilize a reduced intensity regimen.
More about...
Your opinion matters
15 votes - 82 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox